When did Sunshine Biopharma (SBFM) sign and date the settlement-related filing?

The settlement agreement is dated July 8, 2026, and the related report is signed on behalf of Sunshine Biopharma by its CEO, Dr. Steve N. Slilaty, on July 10, 2026.

Sunshine Biopharma settles dispute with Nora ex-president

Q: What agreement did Sunshine Biopharma (SBFM) enter into on July 8, 2026?

Sunshine Biopharma entered into an agreement of transaction and mutual release with Nora Pharma Inc. and former Nora president Malek Chamoun, resolving a dispute between the parties through a defined settlement payment.

Q: How much is Sunshine Biopharma (SBFM) paying in the settlement with Malek Chamoun?

Sunshine Biopharma agreed to pay CAD$1,500,000, described as approximately US$1,058,565, to former Nora Pharma president Malek Chamoun as full and final settlement of a dispute between them.

Q: Who are the parties to Sunshine Biopharma’s (SBFM) Release Agreement?

The Release Agreement is among Sunshine Biopharma Inc., its wholly owned subsidiary Nora Pharma Inc., and Malek Chamoun, who previously served as president of Nora Pharma, settling a dispute between these parties.

Q: What is the purpose of the settlement disclosed by Sunshine Biopharma (SBFM)?

The payment of CAD$1,500,000 to Malek Chamoun is described as being in full and final settlement of a dispute between Sunshine Biopharma, its subsidiary Nora Pharma, and Mr. Chamoun, and is tied to a mutual release agreement.

Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Sunshine Biopharma Inc., through its wholly owned subsidiary Nora Pharma Inc., entered into an agreement of transaction and mutual release with Nora’s former president, Malek Chamoun, on July 8, 2026. Under this agreement, Sunshine Biopharma agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties. The agreement functions as a comprehensive release, aiming to conclude outstanding claims between the company, Nora, and Mr. Chamoun.

Insights

Settlement resolves an internal dispute with a defined cash cost.

The company committed to pay CAD$1,500,000 (about US$1,058,565) to Nora Pharma’s former president, Malek Chamoun, under a transaction and mutual release agreement. This brings a specific dispute to a contractual conclusion and should reduce management distraction around this issue.

The cash payment represents an outflow from Sunshine Biopharma, but the filing does not quantify its scale relative to revenue or cash on hand. The agreement is dated July 8, 2026, with the form signed on July 10, 2026, providing a clear timeline for when the settlement obligations were established.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Settlement amount: CAD$1,500,000 Approximate US dollar equivalent: US$1,058,565 Agreement date: July 8, 2026 +2 more

5 metrics

Settlement amount CAD$1,500,000 Cash payment agreed to be paid to former Nora Pharma president in full and final settlement of a dispute

Approximate US dollar equivalent US$1,058,565 Approximate U.S. dollar value of the CAD$1,500,000 settlement payment

Agreement date July 8, 2026 Date Sunshine Biopharma and Nora Pharma entered into the Release Agreement with Malek Chamoun

Filing signature date July 10, 2026 Date the report was signed by the Chief Executive Officer of Sunshine Biopharma

Exhibit number for Release Agreement 10.1 Exhibit in which the full text of the Release Agreement is filed

Key Terms

material definitive agreement, mutual release, wholly-owned subsidiary, full and final settlement, +1 more

5 terms

material definitive agreement regulatory

"Item 1.01 Entry into a Material Definitive Agreement."

A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.

mutual release legal

"entered into an agreement of transaction and mutual release"

wholly-owned subsidiary financial

"the Company’s wholly-owned subsidiary, Nora Pharma Inc."

A wholly-owned subsidiary is a company whose entire ownership is held by another company, called the parent, so the parent controls all shares, board appointments and major decisions. For investors this matters because the subsidiary’s profits, losses, assets and liabilities are treated as part of the parent’s financial picture, affecting valuation and risk exposure — imagine a parent owning a single storefront outright and consolidating its receipts and bills into the parent’s books.

full and final settlement legal

"in full and final settlement of a dispute between the parties"

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did Sunshine Biopharma (SBFM) enter into on July 8, 2026?

Sunshine Biopharma entered into an agreement of transaction and mutual release with Nora Pharma Inc. and former Nora president Malek Chamoun, resolving a dispute between the parties through a defined settlement payment.

How much is Sunshine Biopharma (SBFM) paying in the settlement with Malek Chamoun?

Sunshine Biopharma agreed to pay CAD$1,500,000, described as approximately US$1,058,565, to former Nora Pharma president Malek Chamoun as full and final settlement of a dispute between them.

Who are the parties to Sunshine Biopharma’s (SBFM) Release Agreement?

The Release Agreement is among Sunshine Biopharma Inc., its wholly owned subsidiary Nora Pharma Inc., and Malek Chamoun, who previously served as president of Nora Pharma, settling a dispute between these parties.

What is the purpose of the settlement disclosed by Sunshine Biopharma (SBFM)?

The payment of CAD$1,500,000 to Malek Chamoun is described as being in full and final settlement of a dispute between Sunshine Biopharma, its subsidiary Nora Pharma, and Mr. Chamoun, and is tied to a mutual release agreement.

Where can investors find the full terms of Sunshine Biopharma’s (SBFM) Release Agreement?

The company states that the summary is qualified by the full Release Agreement, which is filed as Exhibit 10.1, allowing investors to review the complete contractual terms in that exhibit.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/10/2026 - 04:54 PM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 8, 2026

SUNSHINE BIOPHARMA INC.

(Exact name of registrant as specified in its charter)

Colorado

001-41282

20-5566275

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)

333 Las Olas Way, CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (Zip Code)

(954) 330-6684

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol	Name of Each Exchange on Which Registered

Common Stock, par value $0.001	SBFM	The Nasdaq Stock Market LLC
Common Stock Purchase Warrants	SBFMW	The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On July 8, 2026, Sunshine Biopharma Inc. (the “Company”) and the Company’s wholly-owned subsidiary, Nora Pharma Inc. (“Nora”) entered into an agreement of transaction and mutual release (the “Release Agreement”) with Malek Chamoun, the former president of Nora. Pursuant to the Release Agreement, the Company agreed to pay Mr. Chamoun CAD$1,500,000 (approximately US$1,058,565) in full and final settlement of a dispute between the parties.

The foregoing description of the Release Agreement is qualified by reference to the full text of the Release Agreement, which is filed as an exhibit to this report.

Item 9.01. Financial Statements and Exhibits.

Exhibit No.		Description
10.1		Release Agreement
104		Cover Page Interactive Data File (formatted in Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 10, 2026	SUNSHINE BIOPHARMA INC.


	By: /s/ Dr. Steve N. Slilaty
	Name: Dr. Steve N. Slilaty Title: Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents

Agreements & Contracts

EX-10.1 RELEASE AGREEMENT 54.0 KB

Sunshine Biopharma settles dispute with Nora ex-president

Rhea-AI Filing Summary